Fluoride Pharmacokinetics in Urine and Plasma Following Multiple Doses of MK‐8507, an Investigational, Oral, Once‐Weekly Nonnucleoside Reverse Transcriptase Inhibitor

MK‐8507 is an investigational HIV‐1 nonnucleoside reverse transcriptase inhibitor being developed for the treatment of HIV‐1 infection. MK‐8507 contains 2 trifluoromethyl groups that may result in fluoride release through metabolism, but the extent of MK‐8507–related fluoride release in humans has y...

Descripción completa

Detalles Bibliográficos
Autores principales: Gillespie, Gillian, Jackson Rudd, Deanne, Zhang, Saijuan, Schaeffer, Andrea, Tomek, Charles, Larson, Patrick, Stoch, S. Aubrey, Iwamoto, Marian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Pharmacokinetics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9298720/
https://www.ncbi.nlm.nih.gov/pubmed/34435371
http://dx.doi.org/10.1002/jcph.1957

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9298720/
https://www.ncbi.nlm.nih.gov/pubmed/34435371
http://dx.doi.org/10.1002/jcph.1957

Ejemplares similares